Chapter 004

Pharmacogenetics and Pharmacogenomics

David W. Hein and Denis M. Grant

CITED REFERENCES

  1. Abrahams E, Ginsburg GS, Silver M: The Personalized Medicine Coalition: goals and strategies. Am J Pharmacogenomics 5:345-355, 2005. PUBMED Abstract
  2. Arranz MJ, de Leon J: Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 12:707-747, 2007. PUBMED Abstract
  3. Arranz MJ, Munro J, Birkett J, et al: Pharmacogenetic prediction of clozapine response. Lancet 355:1615-1616, 2000. PUBMED Abstract
  4. Begley S: Screening for genes: matching medications to your genetic heritage. Newsweek Feb. 8, 1999. Available at: http://www.newsweek.com/id/87207. Accessed January 10, 2010.
  5. Dalen P, Frengell C, Dahl ML, et al: Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit 19:543-544, 1997. PUBMED Abstract
  6. Daly AK: Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 17:27-41, 2003. PUBMED Abstract
  7. Daly AK: Pharmacogenetics of the cytochromes P450. Curr Top Med Chem 4:1733-1744, 2004. PUBMED Abstract
  8. Deeken JF, Slack R, Marshall JL: Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question. Cancer 113:1502-1510, 2008. PUBMED Abstract
  9. de Leon J, Arranz MJ, Ruano G: Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med 28:599-617, 2008. PUBMED Abstract
  10. Desta Z, Zhao X, Shin JG, et al: Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913-958, 2002. PUBMED Abstract
  11. Eichelbaum M, Ingelman-Sundberg M, Evans WE: Pharmacogenomics and individualized drug therapy. Annu Rev Med 57:119-137, 2006. PUBMED Abstract
  12. Evans WE: Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 26:186-191, 2004. PUBMED Abstract
  13. Evans WE, McLeod HL: Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med 348:538-549, 2003. PUBMED Abstract
  14. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491, 1999. PUBMED Abstract
  15. Evans WE, Relling MV: Moving towards individualized medicine with pharmacogenomics. Nature 429:464-468, 2004.
  16. Flockhart DA, O’Kane D, Williams MS, et al: Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 10:139-150, 2008. PUBMED Abstract
  17. Fretland AJ, Leff MA, Doll MA, et al: Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics 11:207-215, 2001. PUBMED Abstract
  18. Frueh FW, Amur S, Mummaneni P, et al: Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy 28:992-998, 2008.
  19. Furuta T, Ohashi K, Kamata T, et al: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129:1027-1030, 1998. PUBMED Abstract
  20. Gardiner SJ, Begg EJ: Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 58:521-590, 2006. PUBMED Abstract
  21. Giacomini KM, Brett CM, Altman RB, et al: The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 81:328-345, 2007. PUBMED Abstract
  22. Grant DM: Pharmacogenetic and biologic markers of unintended drug effects. In Hartzema AG, Tilson HH, Chan KA, editors: Pharmacoepidemiology and therapeutic risk management, Cincinnati, 2008, Harvey Whitney Books.
  23. Grant DM, Kalow W: Pharmacogenetics and pharmacogenomics. In Kalant H, Grant DM, Mitchell J, editors. Principles of medical pharmacology, ed 7, Toronto, 2007, Saunders Elsevier Canada.
  24. Hein DW, Doll MA, Fretland AJ, et al: Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9:29-42, 2000.
  25. Ingelman-Sundberg M: Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 250:186-200, 2001. PUBMED Abstract
  26. Ingelman-Sundberg M, Oscarson M, McLellan RA: Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 20:342-349, 1999. PUBMED Abstract
  27. Innocenti F, Iyer L, Ratain MJ: Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos 29:596-600, 2001. PUBMED Abstract
  28. Johnson JA, Lima JJ: Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges. Pharmacogenetics 13:525-534, 2003.
  29. Kalow W: Interethnic differences in drug response. In Kalow W, Meyer UA, Tyndale RF, editors: Pharmacogenomics, ed 2, Boca Raton, 2005, Taylor & Francis.
  30. Kalow W, Meyer UA, Tyndale RF: Pharmacogenomics. In Swarbrick J, editor: Drugs and the pharmaceutical sciences, ed 2, vol 156, Boca Raton, 2005, Taylor & Francis.
  31. Krynetski EY, Evans WE: Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology 61:136-146, 2000.
  32. La Du BN, Bartels CF, Nogueira CP, et al: Phenotypic and molecular biological analysis of human butyrylcholinesterase variants. Clin Biochem 23:423-431, 1990.
  33. Liggett SB: Pharmacogenetics of beta-1- and beta-2-adrenergic receptors. Pharmacology 61:167-173, 2000. PUBMED Abstract
  34. Lima JJ, Thomason DB, Mohamed MH, et al: Impact of genetic polymorphisms of the β2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 65:519-525, 1999.
  35. MacLennan DH, Phillips MS: Malignant hyperthermia. Science 256:789-794, 1992. PUBMED Abstract
  36. McLeod HL, Krynetski EY, Relling MV, et al: Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14:567-572, 2000.
  37. Marzolini C, Paus E, Buclin T, et al: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13-33, 2004. PUBMED Abstract
  38. Marzolini C, Tirona RG, Kim RB: Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 5:273-282, 2004. PUBMED Abstract
  39. Marzolini C, Tirona RG, Kim RB: Pharmacogenetics of drug transporters. In Kalow W, Meyer UA, Tyndale RF, editors: Pharmacogenomics, ed 2, Boca Raton, 2005, Taylor & Francis.
  40. Mattison LK, Soong R, Diasio RB: Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 3:485-492, 2002.
  41. Nebert DW, Zhang G, Vesell ES: From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev 40:187-224, 2008. PUBMED Abstract
  42. Palmer LI, Martin RC, Hein DW: Chemopreventive drug treatment in subjects with genetic predisposition to cancer: prescriber liability and healthcare disparities. Pharmacogenomics 5:319-329, 2004.
  43. Poirier J, Sevigny P: Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer’s disease. J Neural Transm Suppl 53:199-207, 1998. PUBMED Abstract
  44. Regieli JJ, Jukema JW, Grobbee DE, et al: CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J 29:2792-2799, 2008.
  45. Relling MV, Giacomini KM: Pharmacogenetics. In Brunton LL, Lazo JS, Parker KL, editors: Goodman and Gilman’s the pharmacological basis of therapeutics, ed 11, New York, 2006, McGraw-Hill.
  46. Rettie AE, Jones JP: Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 45:477-494, 2005. PUBMED Abstract
  47. Roden DM, Altman RB, Benowitz NL, et al: Pharmacogenomics: challenges and opportunities. Ann Intern Med 145:749-757, 2006. PUBMED Abstract
  48. Rollason V, Samer C, Piguet V, et al: Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics 9:905-933, 2008. PUBMED Abstract
  49. Roses AD: Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov 7:807-817, 2008. PUBMED Abstract
  50. Rothstein MA, Epps PG: Ethical and legal implications of pharmacogenomics. Nat Rev Genet 2:228-231, 2001. PUBMED Abstract
  51. Schroth W, Antoniadou L, Fritz P, et al: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187-5193, 2007.
  52. Shi MM: Technologies for individual genotyping: detection of genetic polymorphisms in drug targets and disease genes. Am J Pharmacogenomics 2:197-205, 2002. PUBMED Abstract
  53. Sillon G, Joly Y, Feldman S, et al: An ethical and legal overview of pharmacogenomics: perspectives and issues. Med Law 27:843-857, 2008. PUBMED Abstract
  54. Stamer UM, Stuber F: The pharmacogenetics of analgesia. Expert Opin Pharmacother 8:2235-2245, 2007. PUBMED Abstract
  55. Stearns V, Rae JM: Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? Expert Rev Mol Med 10:e34, 2008.
  56. Stowell KM: Malignant hyperthermia: a pharmacogenetic disorder. Pharmacogenomics 9:1657-1672, 2008. PUBMED Abstract
  57. Strassburg CP: Pharmacogenetics of Gilbert’s syndrome. Pharmacogenomics 9:703-715, 2008. PUBMED Abstract
  58. Strassburg CP, Kalthoff S, Ehmer U: Variability and function of family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A), Crit Rev Clin Lab Sci 45:485-530, 2008. PUBMED Abstract
  59. Weber WW: Pharmacogenetics, New York, 1997, Oxford University Press.
  60. Weber WW, Hein DW: N-acetylation pharmacogenetics. Pharmacol Rev 37:25-79, 1985. PUBMED Abstract
  61. Weinshilboum R: Inheritance and drug response. N Engl J Med 348:529-537, 2003. PUBMED Abstract
  62. Wilkins MR, Roses AD, Clifford CP: Pharmacogenetics and the treatment of cardiovascular disease. Heart 84:353-354, 2000. PUBMED Abstract
  63. Zanger UM, Turpeinen M, Klein K, et al: Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093-1108, 2008. PUBMED Abstract
  64. Zhou SF, Di YM, Chan E, et al: Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 9:738-784, 2008. PUBMED Abstract

GENERAL REFERENCES

  1. Eichelbaum M, Ingelman-Sundberg M, Evans WE: Pharmacogenomics and individualized drug therapy, Annu Rev Med 57:119-137, 2006.
  2. Grant DM: Pharmacogenetic and biologic markers of unintended drug effects. In Hartzema AG, Tilson HH, Chan KA, editors: Pharmacoepidemiology and therapeutic risk management, Cincinnati, 2008, Harvey Whitney Books.
  3. Grant DM, Kalow W: Pharmacogenetics and pharmacogenomics. In Kalant H, Grant DM, Mitchell J, editors. Principles of medical pharmacology, ed 7, Toronto, 2007, Saunders Elsevier Canada.
  4. Ingelman-Sundberg M: Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy, J Intern Med 250:186-200, 2001. PUBMED Abstract
  5. Rothstein MA, editor: Pharmacogenomics: social, ethical, and clinical dimensions, Hoboken, 2003, John Wiley & Sons.